01 1Curia
01 1PENTOBARBITAL SODIUM, USP DRUG SUBSTANCE
01 1U.S.A
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2014-08-07
Pay. Date : 2013-10-01
DMF Number : 25926
Submission : 2012-03-30
Status : Active
Type : II
20
Curia New York Inc, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
They are recognized for Curia- A partner for the pharma and biotech industries to improve patient outcomes & quality of life.
One of their notable products is PENTOBARBITAL SODIUM, USP DRUG SUBSTANCE, with a corresponding US DMF Number 25926.
Remarkably, this DMF maintains an Active status since its submission on March 30, 2012, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of August 07, 2014, and payment made on October 01, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II
